Eli Lilly slashes insulin prices by 70%, places $35 monthly out-of-pocket cap
dml5050/iStock via Getty Images
- Eli Lilly (NYSE:LLY) is cutting the prices of its insulin drugs by 70% and introducing a program that will cap out-of-pocket expenses at $35 per month.
- The reductions impact Insulin Lispro, Humalog (insulin lispro injection), and Humulin (insulin human).
- The drug giant is also launchign Rezvoglar (insulin glargine-aglr), a basal insulin that is biosimilar to Sanofi's (SNY) Lantus (insulin glargine) injection, for $92 per five pack, a 78% discount to Lantus, beginning April 1.
- The $35 cap applies to individuals with commercial insurance at retail pharmacies.
- Those without insurance can get get Lilly (LLY) insulins under the $35 cap through the Lilly Insulin Value Program.
- In August 2022, a the Inflation Reduction Act passed the Senate with a provision on capping monthly insulin out-of-pockets costs for commercial insurance stripped.